Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective pilot trial of multimodal targeted therapy (RIST protocol) in relapsed or refractory high-grade pineoblastoma
2015-004304-27Phase 2Completed
- Sponsor
- Universitätsklinikum Regensburg
- Start
- Mar 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of dasatinib, temozolomide, sirolimus and irinotecan in pineoblastoma (PB), sponsored by Universitätsklinikum Regensburg. Primary endpoint: Progression-free survival. Started Mar 2016; status: completed.
02
Drugs
dasatinibtemozolomidesirolimusirinotecan
03
Conditions
pineoblastoma (PB)
Beyond the preview
Go deeper on 2015-004304-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004304-27.